MX359288B - Forma iv del clorhidrato de ivabradina. - Google Patents

Forma iv del clorhidrato de ivabradina.

Info

Publication number
MX359288B
MX359288B MX2014005362A MX2014005362A MX359288B MX 359288 B MX359288 B MX 359288B MX 2014005362 A MX2014005362 A MX 2014005362A MX 2014005362 A MX2014005362 A MX 2014005362A MX 359288 B MX359288 B MX 359288B
Authority
MX
Mexico
Prior art keywords
hydrochloride form
ivabradine hydrochloride
ivabradine
preparation
pharmaceutical composition
Prior art date
Application number
MX2014005362A
Other languages
English (en)
Other versions
MX2014005362A (es
Inventor
Lopez Rafael Prohens
Vallet Cristina Puigjaner
Cañero Rafael Barbas
Via Josep Martí
Río Pericacho José Luís Del
Original Assignee
Urquima Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46934559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX359288(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Urquima Sa filed Critical Urquima Sa
Publication of MX2014005362A publication Critical patent/MX2014005362A/es
Publication of MX359288B publication Critical patent/MX359288B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

Clorhidrato de ivabradina Forma IV, su composición farmacéutica, procedimiento para su preparación y su uso como ingrediente terapéuticamente activo.
MX2014005362A 2011-11-04 2012-09-21 Forma iv del clorhidrato de ivabradina. MX359288B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11382339.7A EP2589594A1 (en) 2011-11-04 2011-11-04 Ivabradine hydrochloride Form IV
PCT/EP2012/068615 WO2013064307A1 (en) 2011-11-04 2012-09-21 Ivabradine hydrochloride form iv

Publications (2)

Publication Number Publication Date
MX2014005362A MX2014005362A (es) 2015-01-22
MX359288B true MX359288B (es) 2018-09-20

Family

ID=46934559

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014005362A MX359288B (es) 2011-11-04 2012-09-21 Forma iv del clorhidrato de ivabradina.

Country Status (21)

Country Link
US (3) US9139531B2 (es)
EP (3) EP2589594A1 (es)
JP (3) JP6359971B2 (es)
KR (1) KR102050117B1 (es)
AU (1) AU2012331395B2 (es)
BR (1) BR112014010767B1 (es)
CA (1) CA2854549C (es)
CY (1) CY1119798T1 (es)
DK (1) DK2773620T3 (es)
ES (1) ES2562843T3 (es)
HR (1) HRP20171511T1 (es)
HU (1) HUE034996T2 (es)
LT (1) LT2773620T (es)
MX (1) MX359288B (es)
PL (1) PL2773620T3 (es)
PT (1) PT2773620T (es)
RS (1) RS56464B1 (es)
RU (1) RU2619121C2 (es)
SI (1) SI2773620T1 (es)
WO (1) WO2013064307A1 (es)
ZA (1) ZA201403073B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2964367B2 (ja) 1991-12-19 1999-10-18 株式会社オハラ 光学素子成形用型
EP2589594A1 (en) * 2011-11-04 2013-05-08 Urquima S.A. Ivabradine hydrochloride Form IV
EP2780327A1 (en) 2011-11-14 2014-09-24 Cadila Healthcare Limited Polymorphic forms of ivabradine hydrochloride
HUE047705T2 (hu) 2013-03-19 2020-05-28 Chemo Res S L Ivabradin-hidroklorid új polimorfja és eljárás elõállítására
ITMI20130684A1 (it) * 2013-04-24 2014-10-25 Chemo Res S L Nuovo polimorfo del cloridrato di ivabradina e metodo per la sua preparazione
CZ305096B6 (cs) 2013-10-02 2015-04-29 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (S)-mandlové kyseliny a její farmaceutická kompozice
ES2672472T3 (es) 2013-12-12 2018-06-14 Synthon Bv Composición farmacéutica que comprende ivabradina amorfa
SI2774606T1 (sl) * 2014-02-14 2019-05-31 Synthon B.V. Farmacevtski sestavek, ki obsega polimorf IV ivabradin hidroklorida
CZ2014478A3 (cs) 2014-07-10 2015-09-16 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (R)-mandlové kyseliny a její farmaceutická kompozice
GR1008821B (el) 2015-06-11 2016-08-01 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα που περιλαμβανει υδροχλωρικη ιβαμπραδινη και μεθοδος παρασκευης αυτου
TR201703066A2 (tr) 2017-02-28 2018-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi İvabradi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari
EP3366282B1 (en) 2017-02-28 2025-10-01 Sanovel Ilac Sanayi ve Ticaret A.S. Solid oral pharmaceutical compositions of ivabradine
TWI791621B (zh) 2017-09-19 2023-02-11 日商三井化學股份有限公司 眼鏡
US20230181472A1 (en) * 2018-10-30 2023-06-15 Amgen Inc. Process of making ivabradine hydrochloride drug product
IT202000025312A1 (it) 2020-10-26 2022-04-26 Cambrex Profarmaco Milano S R L Processi per la preparazione di polimorfi di ivabradina hcl

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2681862B1 (fr) 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
FR2868777B1 (fr) 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
EP2097383B1 (en) * 2006-11-30 2012-02-08 Cadila Healthcare Limited Process for preparation of ivabradine hydrochloride
WO2008125006A1 (fr) * 2007-04-12 2008-10-23 Utopharm (Shanghai) Co., Ltd Procédés de préparation du chlorhydrate d'ivabradine et de sa forme cristalline stable
KR101478855B1 (ko) * 2007-05-30 2015-01-02 인드-스위프트 래버러토리즈 리미티드 이바브라딘 히드로클로라이드 및 그의 다형태의 제조방법
CN101597261A (zh) 2008-06-06 2009-12-09 北京深蓝海生物医药科技有限公司 无定形盐酸伊伐布雷定
US20100323471A1 (en) 2008-08-21 2010-12-23 Applied Materials, Inc. Selective Etch of Laser Scribed Solar Cell Substrate
CN101768117B (zh) 2008-12-29 2014-05-07 北京德众万全药物技术开发有限公司 一种盐酸伊伐布雷定晶型及其制备方法
CN101463008A (zh) 2009-01-11 2009-06-24 山东鲁抗辰欣药业有限公司 盐酸伊伐布雷定无定型物及其制备方法
CN101805289A (zh) 2009-02-17 2010-08-18 成都威克药业有限责任公司 伊伐布雷定盐酸盐的ω-晶型、其制备方法和药物组合物
CN102050784B (zh) 2009-11-04 2014-07-09 扬子江药业集团北京海燕药业有限公司 一种无定型盐酸伊伐布雷定的制备方法
SI23290A (sl) 2010-02-12 2011-08-31 Krka D.D., Novo Mesto Nove oblike ivabradin hidroklorida
WO2012025940A1 (en) 2010-08-25 2012-03-01 Cadila Healthcare Limited Polymorphic form of ivabradine hydrochloride and process for preparation thereof
EP2589594A1 (en) * 2011-11-04 2013-05-08 Urquima S.A. Ivabradine hydrochloride Form IV
EP2780327A1 (en) * 2011-11-14 2014-09-24 Cadila Healthcare Limited Polymorphic forms of ivabradine hydrochloride

Also Published As

Publication number Publication date
ZA201403073B (en) 2015-03-25
KR20140101753A (ko) 2014-08-20
PL2773620T3 (pl) 2017-12-29
CY1119798T1 (el) 2018-06-27
EP2773620A1 (en) 2014-09-10
PT2773620T (pt) 2017-10-19
HUE034996T2 (en) 2018-05-02
US9309201B2 (en) 2016-04-12
RS56464B1 (sr) 2018-01-31
AU2012331395A1 (en) 2014-05-22
BR112014010767A2 (pt) 2017-06-13
CA2854549C (en) 2019-08-27
US20150344435A1 (en) 2015-12-03
EP3263556A1 (en) 2018-01-03
MX2014005362A (es) 2015-01-22
JP6359971B2 (ja) 2018-07-18
CA2854549A1 (en) 2013-05-10
RU2014122261A (ru) 2015-12-10
HRP20171511T1 (hr) 2017-11-17
US9139531B2 (en) 2015-09-22
LT2773620T (lt) 2017-10-25
ES2562843T1 (es) 2016-03-08
EP2589594A1 (en) 2013-05-08
JP2018123154A (ja) 2018-08-09
KR102050117B1 (ko) 2020-01-08
DK2773620T3 (en) 2017-10-09
US20140315890A1 (en) 2014-10-23
US20160289192A1 (en) 2016-10-06
EP2773620B1 (en) 2017-08-16
BR112014010767B1 (pt) 2021-03-09
JP2014532673A (ja) 2014-12-08
RU2619121C2 (ru) 2017-05-12
WO2013064307A1 (en) 2013-05-10
SI2773620T1 (sl) 2017-11-30
ES2562843T3 (es) 2017-10-19
JP2017178965A (ja) 2017-10-05
AU2012331395B2 (en) 2016-11-17

Similar Documents

Publication Publication Date Title
MX359288B (es) Forma iv del clorhidrato de ivabradina.
TN2014000030A1 (en) Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators
WO2011130615A3 (en) Preparation of lacosamide
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
EP2522653A4 (en) BIGUANIDE DERIVATIVE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE BIGUANIDE DERIVATIVE AS AN ACTIVE SUBSTANCE
PL2808325T3 (pl) Podstawione azole, przeciwwirusowy składnik czynny, kompozycja farmaceutyczna, sposób ich wytwarzania i stosowania
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
MX350447B (es) Composicion farmaceutica de disolucion rapida.
EP3072506A4 (en) Carrier for drug delivery and conjugate, composition containing same, and method for administering same
IL231170A (en) Nitrate mustard derivative compound, pharmaceutical preparation, use of drug preparation and compound for use as a drug
TW201144301A (en) Processes for preparing linezolid
IN2015DN03984A (es)
IL230463A (en) Benzamides, their preparation and their pharmaceutical preparations
WO2014076712A3 (en) Lurasidone hydrochloride solid dispersion
PH12013502325A1 (en) Drug delivery system
IL223872A (en) Pyrazoloquinoline derivatives and intermediates, process for preparation, use and pharmaceutical preparations and preparations containing them
JO3112B1 (ar) تركيبة دوائية سريعة التحلل
WO2014203275A3 (en) An improved process for the preparation of apixaban and intermediates thereof
ZA201400646B (en) Topical ophthalmological pharmaceutical composition containing regorafenib
MX2015005762A (es) Producto de comicronizacion que comprende acetato de ulipristal.
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
MX2014004210A (es) Derivados de 2-oxo-piperidinilo.
PT2476420E (pt) Composição farmacêutica com atividade antimicrobiana e de cicatrização rápida para administração externa, e processo de preparação da mesma
MX367773B (es) Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
MX2014006201A (es) Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse.

Legal Events

Date Code Title Description
FG Grant or registration